The significant growth in Moderna's stock value over the past 5 years, as highlighted by the article, suggests a strong performance and potential for continued positive momentum. This is based on the historical data provided, including the annualized return of 23.65% and an average annual return of 35.34%, which are indicators of the company's robust financial health and market position.